Teleflex Incorporated (TFX) Latest Company News

Sep 4, 2026, 10:30 UTC
Teleflex announced it will showcase its Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 in Copenhagen.
Source:
- businesswire.com
Aug 6, 2026, 15:00 UTC
The U.S. FDA approved Teleflex's freeze-dried plasma product EzPlaz for use in treating life-threatening bleeding in austere environments.
Source:
- businessinsider.com
Aug 6, 2026, 10:45 UTC
Teleflex Incorporated's Board of Directors declared a quarterly cash dividend of $0.34 per share of common stock, payable on September 30, 2026, to shareholders of record on August 14, 2026.
Source:
- businesswire.com
Aug 6, 2026, 10:30 UTC
Teleflex reported second quarter 2026 financial results, with revenue from continuing operations of $570.3 million, up 28.9% year-over-year, and GAAP diluted EPS of $0.96, down from $1.54 in the prior year period.
Source:
Aug 6, 2026, 00:00 UTC
Teleflex Inc repurchased $250 million of its common stock in Q2 2026 and authorized an additional $250 million accelerated share repurchase.
Aug 6, 2026, 00:00 UTC
Teleflex Inc repaid $700 million of its Term Loan A2 using proceeds from the OEM divestiture.
Aug 3, 2026, 20:15 UTC
Teleflex completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash.
Source:
Jul 21, 2026, 12:44 UTC
Teleflex Incorporated has been awarded a national group purchasing agreement for central venous access products with Premier, Inc.
Source:
- businesswire.com
Jun 15, 2026, 00:00 UTC
Teleflex Inc issued $500,000,000 of 5.875% Senior Notes due January 2032.
Jun 9, 2026, 00:00 UTC
Teleflex Inc. appointed Stuart A. Randle as Interim President and Chief Executive Officer, effective June 8, 2026, with a special restricted stock unit award valued at $600,000.
Jun 1, 2026, 11:45 UTC
Teleflex Incorporated commenced a private offering of $500 million of senior notes due 2032, with proceeds to redeem its outstanding 4.625% Senior Notes due 2027.
Source:
- businesswire.com
- businesswire.com

TFX

Teleflex announced it will showcase its Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 in Copenhagen.

The U.S. FDA approved Teleflex's freeze-dried plasma product EzPlaz for use in treating life-threatening bleeding in austere environments.

Teleflex Incorporated's Board of Directors declared a quarterly cash dividend of $0.34 per share of common stock, payable on September 30, 2026, to shareholders of record on August 14, 2026.

Teleflex reported second quarter 2026 financial results, with revenue from continuing operations of $570.3 million, up 28.9% year-over-year, and GAAP diluted EPS of $0.96, down from $1.54 in the prior year period.

Teleflex Inc repurchased $250 million of its common stock in Q2 2026 and authorized an additional $250 million accelerated share repurchase.

Teleflex Inc repaid $700 million of its Term Loan A2 using proceeds from the OEM divestiture.

Teleflex completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash.

Teleflex Incorporated has been awarded a national group purchasing agreement for central venous access products with Premier, Inc.

Teleflex Inc issued $500,000,000 of 5.875% Senior Notes due January 2032.

Teleflex Inc. appointed Stuart A. Randle as Interim President and Chief Executive Officer, effective June 8, 2026, with a special restricted stock unit award valued at $600,000.

Teleflex Incorporated commenced a private offering of $500 million of senior notes due 2032, with proceeds to redeem its outstanding 4.625% Senior Notes due 2027.